Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.53 |
| ▸ | PLK1 | P53350 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 9/20 | 0.49 |
| ▸ | CDK4 | P11802 | 4/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CCND2 | P30279 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601934 | 0.83 | CCNT1 (0.61) | CDK2CDK4CDK1CCNB1CCNA2 | |
| SCHEMBL4819158 | 0.82 | CDK2 (0.60) | KDRPTK2PLK1CDK2CDK4 | |
| SCHEMBL6599765 | 0.82 | CDK2 (0.57) | CDK2CDK4CCNE1CDK1CCNB1 | |
| SCHEMBL5098405 | 0.80 | CDK2 (0.72) | KDRPTK2PLK1CDK2CDK4 | |
| SCHEMBL4826063 | 0.76 | CDK2 (0.58) | KDRPTK2PLK1CDK2CDK4 | |
| SCHEMBL6599298 | 0.75 | CDK2 (0.67) | CDK2CDK4CDK1IKBKB | |
| SCHEMBL5104957 | 0.73 | CDK2 (0.60) | KDRPTK2PLK1CDK2CDK4 | |
| SCHEMBL6596500 | 0.70 | CDK2 (0.64) | KDRPTK2PLK1CDK2CDK4 | |
| SCHEMBL5105343 | 0.70 | CDK2 (0.69) | KDRPTK2PLK1CDK2CDK4 | |
| SCHEMBL5096290 | 0.70 | PRKCD (0.53) | KDRPTK2PLK1CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446105-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-11-04 | — | — | US | disclosed |
| US-20050119291-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
| EP-1485374-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076433-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119291-A1 | Pyrimidine compounds | TYMP, TYMS, CCNT1 | KDR 745/4885PTK2 4227/4885PLK1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.